2026-04-14T04:01:08Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1976632025-11-19T19:07:00Zcom_2072_1057col_2072_478858col_2072_478916col_2072_478917col_2072_478921

One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry Ortega Paz, Luis Arévalos, Victor Fernández Rodríguez, Diego Jiménez Díaz, Víctor Bañeras, Jordi Campo, Gianluca Rodríguez Santamarta, Miguel Díaz, José Francisco Scardino, Claudia Gómez Álvarez, Zaira Pernigotti, Alberto Alfonso, Fernando Amat Santos, Ignacio J. Silvestro, Antonio Rampa, Lorenzo Torre Hernández, José María de la Bastidas, Gabriela Gómez Lara, Josep Bikdeli, Behnood García García, Hector M. Angiolillo, Dominick J. Rodés Cabau, Josep Sabaté, Manel Brugaletta, Salvatore The CV Covid-19 Registry Investigators Infeccions per coronavirus Malalties cardiovasculars COVID-19 SARS-CoV-2 Coronavirus infections Cardiovascular diseases COVID-19 SARS-CoV-2 Background The long-term cardiovascular (CV) outcomes of COVID-19 have not been fully explored. Methods This was an international, multicenter, retrospective cohort study conducted between February and December 2020. Consecutive patients.18 years who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 were included. Patients were classified into two cohorts depending on the nasopharyngeal swab result and clinical status: confirmed COVID-19 (positive RT-PCR) and control (without suggestive symptoms and negative RT-PCR). Data were obtained from electronic records, and clinical follow-up was performed at 1-year. The primary outcome was CV death at 1-year. Secondary outcomes included arterial thrombotic events (ATE), venous thromboembolism (VTE), and serious cardiac arrhythmias. An independent clinical event committee adjudicated events. A Cox proportional hazards model adjusted for all baseline characteristics was used for comparing outcomes between groups. A prespecified landmark analysis was performed to assess events during the post-acute phase (31-365 days). Results A total of 4,427 patients were included: 3,578 (80.8%) in the COVID-19 and 849 (19.2%) control cohorts. At one year, there were no significant differences in the primary endpoint of CV death between the COVID-19 and control cohorts (1.4% vs. 0.8%; HRadj 1.28 [0.562.91]; p = 0.555), but there was a higher risk of all-cause death (17.8% vs. 4.0%; HRadj 2.82 [1.99-4.0]; p = 0.001). COVID-19 cohort had higher rates of ATE (2.5% vs. 0.8%, HRadj 2.26 [1.02-4.99]; p = 0.044), VTE (3.7% vs. 0.4%, HRadj 9.33 [2.93-29.70]; p = 0.001), and serious cardiac arrhythmias (2.5% vs. 0.6%, HRadj 3.37 [1.35-8.46]; p = 0.010). During the post-acute phase, there were no significant differences in CV death (0.6% vs. 0.7%; HRadj 0.67 [0.25-1.80]; p = 0.425), but there was a higher risk of deep vein thrombosis (0.6% vs. 0.0%; p = 0.028). Re-hospitalization rate was lower in the COVID-19 cohort compared to the control cohort (13.9% vs. 20.6%; p = 0.001). Conclusions At 1-year, patients with COVID-19 experienced an increased risk of all-cause death and adverse CV events, including ATE, VTE, and serious cardiac arrhythmias, but not CV death. 2023-05-08T11:11:35Z 2023-05-08T11:11:35Z 2022-12-30 2023-04-14T11:04:32Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://hdl.handle.net/2445/197663 9334182 36583998 eng Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0279333 PLOS ONE, 2022, vol. 17, num. 12, p. e0279333 https://doi.org/10.1371/journal.pone.0279333 cc by (c) Ortega Paz, Luis et al., 2022 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess 18 p. application/pdf application/pdf Public Library of Science (PLoS) Articles publicats en revistes (Medicina)